What is the recommended evaluation and management of a duodenal polyp?

Duodenal Polyp: Evaluation and Management

All duodenal adenomas should be considered for endoscopic resection due to their risk of malignant transformation, with the approach tailored to lesion size, morphology, and patient comorbidities—but non-neoplastic lesions (like gastric heterotopia or Brunner gland hamartomas) do not require resection unless symptomatic or bleeding. 1

Initial Evaluation

Endoscopic Characterization

Every duodenal polyp requires systematic documentation of:

• Size and Paris morphology (flat, sessile, pedunculated)
• Precise location: D1-D4 segment and wall orientation (anterior/posterior/medial/lateral)
• Relationship to ampulla: Identify and photodocument both major and minor papilla to ensure no involvement 1
• Suspected histologic origin: Mucosal vs subepithelial lesion

Use a clear distal attachment device on forward-viewing gastroscope to improve visualization of the papilla and medial wall. Switch to a side-viewing duodenoscope when the papilla cannot be visualized with the gastroscope or for medial wall lesions within 5 cm of the ampulla 1.

Tissue Diagnosis

Obtain biopsies to distinguish:

• Non-neoplastic lesions: Metaplastic foveolar epithelium, gastric heterotopia, Brunner gland hamartomas, hyperplastic polyps
• Neoplastic lesions: Adenomas (most common and clinically important)
• Subepithelial lesions: GISTs, neuroendocrine tumors, lipomas

Critical distinction: Non-neoplastic lesions can mimic adenomas optically. Careful pathologic correlation is essential to exclude dysplasia 1.

Associated Screening

Perform colonoscopy if not done within the past 3 years when a duodenal adenoma is identified, as there is high frequency of concomitant colonic adenomas 1. This applies to both sporadic and syndromic cases.

Do NOT routinely perform capsule endoscopy for sporadic or FAP-associated duodenal adenomas. Reserve small bowel investigation for Peutz-Jeghers syndrome 1.

Management Algorithm

Non-Neoplastic Lesions

No resection required unless:

• Symptomatic (obstruction, pain)
• Bleeding
• Large size (>2 cm for Brunner gland hamartomas) 1

Duodenal Adenomas (Sporadic)

All sporadic duodenal adenomas warrant consideration for endoscopic resection due to malignant potential (5% progress to cancer, 20% to high-grade dysplasia) 1. However, factor in patient comorbidities and life expectancy as the time to malignant transformation is more prolonged than colonic adenomas, and resection carries significantly higher morbidity 1.

Resection Technique by Size:

Lesions <20 mm (flat, non-bulky):

• Cold snare piecemeal resection is preferred for patients with comorbidities
• Mitigates postprocedural bleeding risk to <4%
• Effective with minimal recurrence for lesions <20 mm 1
• Trade-off: Higher recurrence rate (~24%) compared to hot snare 1

Lesions >20 mm or with large Paris Is components:

• Conventional hot snare endoscopic mucosal resection (EMR) is the current standard 1
• Add thermal ablation of post-EMR margin to reduce recurrence from 15-20% to <3-5% 1
• This is safe and effective and should be strongly considered 1

Critical Complications to Anticipate

Postprocedural Bleeding

Bleeding risk is substantially higher than elsewhere in the GI tract:

• Occurs within first 48 hours
• Risk proportional to lesion size
• >3 cm lesions: >25% bleeding risk, potentially life-threatening with hemodynamic compromise 1
• After resuscitation, endoscopic hemostasis is generally effective

For high-risk patients (multiple comorbidities, large lesions ≥30 mm, need to restart anticoagulation, significant intraprocedural bleeding), strongly consider admission for observation 1.

Post-resection management:

• Clear liquid diet overnight, advance as tolerated
• Twice-daily PPI for 6-8 weeks
• Delay anticoagulation/antiplatelet therapy at least 48 hours if acceptable based on indication 1

Perforation

Evaluate the post-resection defect meticulously to identify concerns for perforation 1. Unrecognized perforation is life-threatening and often mandates surgery. The thin retroperitoneal duodenal wall is highly susceptible to injury.

Defect closure considerations:

• Only small oval or larger elliptical defects amenable to complete closure
• Clip mucosa to mucosa (avoid deep muscle layer injury)
• Exercise great caution—clipping the muscular layer can cause tearing 1

Surveillance Protocol

Initial surveillance at 6 months after complete resection 1:

• Recurrence is often diminutive but scarred
• May require avulsion techniques rather than conventional snare resection
• Complete the resection during the initial session—the first attempt provides highest success and lowest complication risk 1

After negative 6-month surveillance:

• Repeat at 1 year
• If clear, then annually for 2-3 years 1

Special Population: Familial Adenomatous Polyposis (FAP)

Consider endoscopic resection for FAP-associated duodenal adenomas based on:

• Size ≥1 cm
• Morphologic characteristics
• Advanced histology (high-grade dysplasia)
• Spiegelman criteria 1

FAP patients have nearly 20% lifetime risk of duodenal adenocarcinoma (now leading cause of death in FAP). Spiegelman stage IV carries 25% cancer risk, though sensitivity for detecting cancer is only 51% 2.

Key Pitfalls to Avoid

1. Do not leave lesions partially resected—make every effort to complete resection during initial session 1
2. Do not underestimate bleeding risk—it is 25% for lesions >3 cm 1
3. Do not perform aggressive forceps biopsy or submucosal tattooing in FAP patients—this interferes with future mucosectomy 1
4. Do not assume all duodenal polyps are adenomas—non-neoplastic lesions are common and do not require resection 1
5. Do not forget colonoscopy—53% of patients with duodenal adenomas have colon adenomas 3